Oragenics Inc. Files 8-K for Material Definitive Agreement
Ticker: OGEN · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1174940
Sentiment: neutral
Topics: material-definitive-agreement, 8-k
TL;DR
Oragenics just signed a big deal, filing an 8-K on 10/11/24.
AI Summary
On October 11, 2024, Oragenics Inc. entered into a material definitive agreement. The company, incorporated in Florida with its principal executive offices in Sarasota, FL, filed this 8-K report on October 15, 2024, detailing the agreement.
Why It Matters
This filing indicates a significant new contract or partnership for Oragenics Inc., which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new opportunities but also potential risks and obligations for the company.
Key Players & Entities
- Oragenics Inc. (company) — Registrant
- October 11, 2024 (date) — Date of earliest event reported
- October 15, 2024 (date) — Filing date
- Sarasota, FL (location) — Principal executive offices
FAQ
What type of material definitive agreement did Oragenics Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on October 11, 2024.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on October 15, 2024.
What is Oragenics Inc.'s principal executive office location?
Oragenics Inc.'s principal executive offices are located at 1990 Main Street, Suite 750, Sarasota, FL 34236.
What is Oragenics Inc.'s IRS Employer Identification Number?
Oragenics Inc.'s IRS Employer Identification Number is 59-3410522.
What is the SIC code for Oragenics Inc.?
The Standard Industrial Classification (SIC) code for Oragenics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,097 words · 4 min read · ~4 pages · Grade level 12.1 · Accepted 2024-10-11 18:25:22
Key Financial Figures
- $30,000 — s Agreement, in an amount not to exceed $30,000 in addition to certain ongoing disburse
- $2,500 — isbursements of its legal counsel up to $2,500 per calendar quarter. In addition, the
- $10,000,000 — s having an aggregate offering price of $10,000,000. The Company will be required to file a
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex1-1.htm (EX-1.1) — 287KB
- ex5-1.htm (EX-5.1) — 15KB
- ex5-1_001.jpg (GRAPHIC) — 28KB
- 0001493152-24-040974.txt ( ) — 630KB
- ogen-20241011.xsd (EX-101.SCH) — 3KB
- ogen-20241011_lab.xml (EX-101.LAB) — 33KB
- ogen-20241011_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 11 th day of October, 2024. ORAGENICS, INC. (Registrant) BY: /s/Janet Huffman Janet Huffman Chief Financial Officer